NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more
NextCell Pharma AB (NXTCL) - Net Assets
Latest net assets as of August 2025: Skr66.39 Million SEK
Based on the latest financial reports, NextCell Pharma AB (NXTCL) has net assets worth Skr66.39 Million SEK as of August 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr76.73 Million) and total liabilities (Skr10.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr66.39 Million |
| % of Total Assets | 86.52% |
| Annual Growth Rate | 21.12% |
| 5-Year Change | -55.77% |
| 10-Year Change | 881.39% |
| Growth Volatility | 178.57 |
NextCell Pharma AB - Net Assets Trend (2015–2025)
This chart illustrates how NextCell Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NextCell Pharma AB (2015–2025)
The table below shows the annual net assets of NextCell Pharma AB from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | Skr66.39 Million | -1.79% |
| 2024-08-31 | Skr67.60 Million | -10.73% |
| 2023-08-31 | Skr75.73 Million | -34.46% |
| 2022-08-31 | Skr115.54 Million | -23.02% |
| 2021-08-31 | Skr150.09 Million | +472.47% |
| 2020-08-31 | Skr26.22 Million | +14.19% |
| 2019-08-31 | Skr22.96 Million | +355.44% |
| 2018-08-31 | Skr5.04 Million | -73.57% |
| 2017-08-31 | Skr19.07 Million | +181.96% |
| 2016-08-31 | Skr6.76 Million | -30.77% |
| 2015-08-31 | Skr9.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NextCell Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5687.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr22.84 Million | 34.40% |
| Other Components | Skr248.41 Million | 374.17% |
| Total Equity | Skr66.39 Million | 100.00% |
NextCell Pharma AB Competitors by Market Cap
The table below lists competitors of NextCell Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
J.S.P. Property Public Company Limited
BK:JSP
|
$9.64 Million |
|
Airthings ASA
PINK:ARTGF
|
$9.64 Million |
|
Eureka Design Public Company Limited
BK:UREKA
|
$9.64 Million |
|
Avonmore Capital & Management Services Limited
NSE:AVONMORE
|
$9.64 Million |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
$9.63 Million |
|
Dongsung Pharm
KO:002210
|
$9.63 Million |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
$9.62 Million |
|
Cadence Opportunities Fund Ltd
AU:CDO
|
$9.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NextCell Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 67,598,961 to 66,389,086, a change of -1,209,875 (-1.8%).
- Net loss of 35,143,091 reduced equity.
- Other factors increased equity by 33,933,216.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-35.14 Million | -52.94% |
| Other Changes | Skr33.93 Million | +51.11% |
| Total Change | Skr- | -1.79% |
Book Value vs Market Value Analysis
This analysis compares NextCell Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.24x to 1.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-08-31 | Skr0.98 | Skr1.21 | x |
| 2016-08-31 | Skr1.29 | Skr1.21 | x |
| 2017-08-31 | Skr2.40 | Skr1.21 | x |
| 2018-08-31 | Skr0.30 | Skr1.21 | x |
| 2019-08-31 | Skr1.47 | Skr1.21 | x |
| 2020-08-31 | Skr1.18 | Skr1.21 | x |
| 2021-08-31 | Skr4.94 | Skr1.21 | x |
| 2022-08-31 | Skr1.68 | Skr1.21 | x |
| 2023-08-31 | Skr1.10 | Skr1.21 | x |
| 2024-08-31 | Skr0.92 | Skr1.21 | x |
| 2025-08-31 | Skr0.87 | Skr1.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NextCell Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -321.31%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.16x
- Recent ROE (-52.94%) is above the historical average (-90.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -105.30% | -147840.73% | 0.00x | 1.26x | Skr-11.27 Million |
| 2016 | -168.72% | -1410.79% | 0.09x | 1.40x | Skr-12.09 Million |
| 2017 | -69.44% | -2560.93% | 0.02x | 1.13x | Skr-15.15 Million |
| 2018 | -278.34% | -2140.98% | 0.08x | 1.69x | Skr-14.54 Million |
| 2019 | -93.46% | -1184.14% | 0.07x | 1.16x | Skr-23.75 Million |
| 2020 | -67.47% | -496.24% | 0.12x | 1.14x | Skr-20.31 Million |
| 2021 | -16.37% | -627.92% | 0.03x | 1.04x | Skr-39.57 Million |
| 2022 | -29.50% | -609.88% | 0.04x | 1.08x | Skr-45.64 Million |
| 2023 | -52.57% | -393.65% | 0.11x | 1.17x | Skr-47.38 Million |
| 2024 | -62.07% | -393.45% | 0.13x | 1.20x | Skr-48.72 Million |
| 2025 | -52.94% | -321.31% | 0.14x | 1.16x | Skr-41.78 Million |
Industry Comparison
This section compares NextCell Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NextCell Pharma AB (NXTCL) | Skr66.39 Million | -105.30% | 0.16x | $9.63 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |